Global Eosinophilic Disorders Market is Segmented By Type (Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis, Hypereosinophilic Syndrome), By Treatment (Medications, Dietary Therapy, Dilation, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The global eosinophilic disorders market reached US$ 150 million in 2023 and is expected to reach US$ 278 million by 2031 growing with a CAGR of 7.1% during the forecast period 2024-2031.
Eosinophilic disorders are a group of conditions characterized by an abnormal increase in eosinophils, a type of white blood cell, in the body. Eosinophilic disorders occur when the body produces too many eosinophils, causing chronic inflammation and tissue damage.
Eosinophils are a normal component of the blood and certain tissues, such as the spleen, lymph nodes, thymus, and submucosal areas of the gastrointestinal, respiratory, and genitourinary tracts. Normal eosinophil counts range from 0 to 450 eosinophils per cubic millimeter of blood.
Market Scope
| Metrics | Details |
| CAGR | 7.1% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$ Mn) |
| Segments Covered | Type, Treatment, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers
Increasing Research & Developments and Approvals of New and Innovative Drugs
The global eosinophilic disorders market has witnessed significant growth due to various recent research and developments. Eosinophilic disorders are usually diagnosed based on medical history and clinical and imaging findings. Also, advanced research and developments in treating eosinophilic disorders help to accelerate market growth.
For instance, in February 2023, AstraZeneca and Amgen’s TEZSPIRE were approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe eosinophilic asthma. The approval is based on results from the PATHFINDER clinical trial program, which included results from the PATH-BRIDGE Phase I trial. EZSPIRE is the first and only biologic approved for patients with severe eosinophilic asthma.
Moreover, key player's strategies such as partnerships & collaboration, and drug approvals would drive this market. For instance, in June 2022, the FDA approved Dupixen (dupilumab) as the first biologic medicine for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), or eosinophilic esophagitis in different age populations. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways.
Also, in March 2022, AstraZeneca that the FDA issued a complete response letter (CRL) regarding its supplemental Biologics License Application (sBLA) for benralizumab. Benralizumab is approved as an add-on maintenance treatment for severe eosinophilic asthma.
Restraints
Factors such as the high cost of the treatment, complications associated with the disorders, limited awareness & diagnosis among people, limited reimbursement policies, and limited treatment options are expected to hamper the market.
Market Segment Analysis
The global eosinophilic disorders market is segmented based on type, treatment, distribution channels, and region.
The medications segment accounted for approximately 70.5% of the global eosinophilic disorders market share
The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment drugs globally have contributed to the growing demand for eosinophilic disorders treatment. According to clinicalTrials.gov, in October 2022, Stanford University in collaboration with Incyte Corporation conducted a clinical trial on Ruxolitinib in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
Moreover, key player strategies such as partnerships & collaborations, and awareness programs would drive this segment growth. For instance, in March 2023, Peking Union Medical College Hospital in collaboration with Beijing Friendship Hospital conducted an interventional study on the Efficacy and Safety of Baricitinib Combined With Glucocorticoid and Glucocorticoid Monotherapy in Proliferative IgG4-RD Patients with Eosinophilia.
The intervention involve the oral drug prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawn in 4 months.
Also, in October 2022, the Gastrointestinal Eosinophilic Disease Program launched at the Digestive Health Institute, Children's Hospital of Colorado by performing the Esophageal String Test (EST) on the eosinophilic gastrointestinal patients. The Esophageal String Test utilizes a simple collection device called EnteroTracker to collect upper gastrointestinal samples from adults and children.
Market Geographical Share
North America accounted for approximately 43.3% of the global eosinophilic disorders market share
North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of conditions such as eosinophilic asthma, eosinophilic gastroenteritis, and eosinophilic esophagitis is driving the demand for eosinophilia therapeutics.
In the U.S., EoE (eosinophilic esophagitis) is a chronic, progressive disease driven by type 2 inflammation that damages the esophagus and impairs its function. In January 2024, approximately 21,000 children under the age of 12 in the U.S. are currently being treated for EoE with unapproved therapies.
Young children with eosinophilic esophagitis have significant unmet medical needs, despite existing treatment options, 40% of these children in the U.S. under the age of 12 continue to experience symptoms of this disease.
In addition, key players in this region introducing awareness programs and new drug approvals would drive this market growth. For instance, in December 2023, the American Partnership for Eosinophilic Disorders (APFED), a leading advocacy organization for eosinophil-associated disease, launched its second awareness campaign in the legendary Times Square in New York City.
Also, in January 2024, The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
Market Segmentation
By Type
- Eosinophilic Esophagitis
- Eosinophilic Gastritis
- Eosinophilic Enteritis
- Eosinophilic Colitis
- Hypereosinophilic Syndrome
By Treatment
- Medications
- Mepolizumab
- Reslizumab
- Benralizumab
- Dupilunab
- Omalizumab
- Imatinib
- Others
- Dietary Therapy
- Dilation
- Others
By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Companies
The major global players in the eosinophilic disorders market include Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., and Hikma Pharmaceuticals among others.
Key Developments
- In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).
- In February 2024, MANDARA Phase III data published in the New England Journal of Medicine showed remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
- In July 2022, Areteia Therapeutics, Inc. announced its launch as a clinical-stage biopharmaceutical company focused on putting asthma patients in better control of their disease with the first potential oral therapy for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole which is a first-in-class oral eosinophil maturation inhibitor.
Why Purchase the Report?
- To visualize the global eosinophilic disorders market segmentation based on type, treatment, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global eosinophilic disorders market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global eosinophilic disorders market report would provide approximately 62 tables, 66 figures, and 182 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
